Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Eli Lilly And Co (LLY) Price & Performance

ProShares UltraShort Bloomberg Natural Gas ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

ProShares UltraShort Bloomberg Natural Gas ETF vs Eli Lilly And Co — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $27.49, while Eli Lilly And Co trades at $1,140.26 (market cap $1.02T). The key difference: Eli Lilly And Co pays a 0.6% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals.

KOLDLLY
Sector
Leveraged / InverseHealth
52-Week High
$49.39$1.24K
52-Week Low
$13.58$625.65
Market Cap
$1.02T
Enterprise Value
$1.06T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares UltraShort Bloomberg Natural Gas ETF

KOLD trades at $28.25, up 4.01% today, with a bullish technical signal from moving averages and strong trend strength indicated by ADX. Recent news highlights natural gas market volatility driven by weather forecasts and storage reports, with the ETF positioned as a tactical trading tool amid price swings around $3/MMBtu (Seeking Alpha, 2026-06-08).

The outlook remains tied to natural gas price movements, with opportunities for short-term gains from volatility but risks from weather-dependent demand shifts and production levels. Investors face commodity price exposure and leverage risks inherent in inverse ETFs.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares UltraShort Bloomberg Natural Gas ETF

KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.

Read more on KOLD

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY